billHR1410\u2022Tuesday, February 18, 2025Analyzed

9/11 Responder and Survivor Health Funding Correction Act of 2025

Neutral
Impact4/10
Healthcare

Summary

HR1410, the 9/11 Responder and Survivor Health Funding Correction Act of 2025, addresses funding for the World Trade Center Health Program. This bill aims to ensure continued healthcare services for 9/11 responders and survivors. The market impact is localized to specific healthcare providers and administrative entities involved in the program.

Key Takeaways

  • 1.HR1410 addresses funding for the World Trade Center Health Program.
  • 2.The bill aims to ensure continued healthcare services for 9/11 responders and survivors.
  • 3.No specific publicly traded companies are direct beneficiaries or losers.
  • 4.Historical precedent shows similar bills have not caused broad market shifts.

Market Implications

This bill has no direct market implications for publicly traded companies. It ensures the continued funding of a specific government healthcare program, which primarily benefits local and regional healthcare providers and the individuals they serve. Investors should not expect any movement in healthcare sector tickers or individual company stocks based on the progression of HR1410.

Full Analysis

HR1410 has been referred to the House Committee on Energy and Commerce. This bill seeks to correct funding shortfalls for the World Trade Center Health Program, which provides medical monitoring and treatment for individuals affected by the 9/11 attacks. The program has faced historical funding challenges, and this legislation aims to secure its long-term solvency. The immediate impact is on the stability of healthcare services for a specific population rather than broad market movements. The money trail for this legislation primarily involves direct appropriations to the World Trade Center Health Program, which is administered by the National Institute for Occupational Safety and Health (NIOSH) within the Centers for Disease Control and Prevention (CDC). Funds are then disbursed to various healthcare providers, clinics, and pharmacies that treat eligible responders and survivors. These are typically local and regional healthcare entities, not publicly traded companies. There are no specific publicly traded companies directly positioned to capture significant new contracts or revenue streams from this bill's passage. Historical precedent for similar funding corrections exists. For example, the James Zadroga 9/11 Health and Compensation Act of 2010 established the program, and subsequent reauthorizations and funding adjustments, such as in 2015, ensured its continuation. These past legislative actions did not trigger significant market reactions in the broader healthcare sector or specific company stock prices, as the funding is highly targeted and does not represent a new market opportunity for large healthcare corporations. The focus was on maintaining existing services rather than expanding them in a way that would drive corporate growth. There are no specific publicly traded winners or losers from this bill. The impact is on the stability of the program itself and the continued provision of care by the network of healthcare providers already serving this population. The bill ensures continued revenue for these existing providers, preventing potential service disruptions. No specific tickers are directly affected. The next step for HR1410 is consideration by the House Committee on Energy and Commerce. If approved, it will move to a floor vote in the House, then to the Senate for consideration, and finally to the President for signature. The timeline for passage is uncertain but could extend through 2025 given the legislative process.

Market Impact Score

4/10
Minimal ImpactModerateMajor Market Event